Alvotech tekur þátt
Alvotech tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanley
August 26, 2024 09:15 ET | Alvotech
Alvotech (NASDAQ: ALVO) tekur þátt í 22. árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanleys í New York. Fulltrúar framkvæmdastjórnar félagsins munu meðal annars sitja fyrir svörum...
Alvotech to Particip
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 09:15 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd...
Alvotech_logo.jpg
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 09:14 ET | Alvotech
REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech skilar mett
Alvotech skilar mettekjum og metframlegð á öðrum ársfjórðungi og á fyrri helmingi ársins
August 15, 2024 16:15 ET | Alvotech
Heildartekjur voru 236 milljónir dollara á fyrri helmingi ársins, sem er meira en tíföldun frá sama tímabili í fyrraTekjur af vörusölu á fyrri helmingi ársins jukust um 190% frá sama tímabili í fyrra...
Alvotech Reports Rec
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
August 15, 2024 16:15 ET | Alvotech
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190%...
Lyfjastofnun Evrópu
Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea
August 15, 2024 04:30 ET | Alvotech
Markaðsleyfi fyrir Evrópu gæti verið veitt á þriðja fjórðungi næsta árs Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Advanz Pharma tilkynntu í dag að Lyfjastofnun...
European Medicines A
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
August 15, 2024 04:30 ET | Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
STADA og Alvotech he
STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu
July 22, 2024 06:35 ET | Alvotech
Fréttatilkynning22. júlí 2024STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu Líftæknilyfjahliðstæðan kemur á markað um leið og einkaleyfi fyrir...
STADA and Alvotech l
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
July 22, 2024 06:35 ET | Alvotech
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights...
Alvotech_logo.jpg
Alvotech Announces Closing of Private Debt Financing
July 11, 2024 04:45 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously...